 | | Vol. 13.17 – 18 August, 2023 |
| |
|
|
| The authors showed a frequent genomic co-deletion of PTEN and signal transducer and activator of transcription 3 (STAT3) in liquid biopsies of patients with metastatic prostate cancer.
[Molecular Cancer] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators found evidence that metformin resistance in prostate cancer cells may be linked to cell cycle reactivation.
[Signal Transduction and Targeted Therapy] |
|
|
|
| Using in silico genomic and transcriptomic tumor data, proteomics analysis and genetically modified cell line models, the authors demonstrated mechanistic links between Speckle-type POZ protein (SPOP) mutations, STING signaling alterations, and PARP inhibitor vulnerabilities.
[Clinical Cancer Research] |
|
|
|
| Investigators demonstrated that LSD1 could demethylate the lysine 270 of FOXA1 in prostate cancer cells, leading to the stabilization of FOXA1 chromatin binding.
[Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers determined that KLB was upregulated in prostate cancer and its expression level was positively correlated with prostate cancer malignant phenotype both in vitro and in vivo.
[Oncogene] |
|
|
|
| The authors found that dioxin or PCB-153 exposure increased hallmarks of growth and metastasis of prostate cancer cells ex vivo and in grafted NOD-SCID mice.
[Oncogene] |
|
|
|
| Scientists report that in vitro downregulation of low-molecular-weight caldesmon promoted epithelial phenotype and reduced spheroid growth in 3D, which was reflected in vivo in reduced formation of metastases in zebrafish prostate cancer xenografts.
[Oncogenesis] |
|
|
|
| Researchers found that SHOX2 expression was significantly raised in prostate cancer (PCa) tissues and was associated with clinicopathological features as well as disease-free survival of PCa patients.
[iScience] |
|
|
|
| Scientists discovered the anti-CRPC effects and underlying mechanisms of small-molecule compounds targeting topoisomerase II and cellular components of DNA damage repair.
[The Prostate] |
|  |
|
|
|
| The authors highlights the advancements in prostate cancer therapeutics and new drug molecules against prostate cancer.
[Frontiers in Oncology] |
|
|
|
|
| The grant award of non-dilutive fund for “An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors”, will be used for the development of Bria-OTS™, BriaCell’s novel personalized off-the-shelf immunotherapies for advanced metastatic cancers.
[BrioCell Therapeutics, Corp.] |
|
|
|
| The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA has approved AKEEGA™ for the treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC.
[Johnson & Johnson] |
|
|
|
|
| October 4 – 6, 2023
Paris, France |
|
|
|
|
|
| | University of South Australia – Adelaide, Australia |
|
|
|
| | Georgia Cancer Center at Augusta University – Augusta, Georgia, United States |
|
|
|
| | Stony Brook University – Stony Brook, New York, United States |
|
|
|
| | Creative Biolabs – New York, New York, United States |
|
|
|
| | The University of Iowa – Iowa City, Iowa, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
